Comparison of the utility of cocaine- and amphetamine-regulated transcript (cart), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1520-1528

  Ramachandran, R ^a   Bech, P ^a   Murphy, K G ^a   Caplin, M E ^b   Patel, M ^a   Vohra, S ^a   Khan, M S ^b,c   Dhillo, W S ^a   Sharma, R ^a,d   Palazzo, F F ^a,d   Win, Z ^a,d   Tan, T ^a   Khoo, B ^b   Meeran, K ^a   Frilling, A ^a   Ghatei, M A ^a   Bloom, S R ^a   Martin, N M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; NERVE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SENSIBILITY; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR REGRESSION; VERY ELDERLY; ADRENAL GLAND NEOPLASMS; BLOOD; CASE CONTROL STUDY; ENDOCRINE SYSTEM EXAMINATION; MIDDLE AGED; NEUROENDOCRINE TUMORS; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; YOUNG ADULT;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOGRANIN A; CHROMOGRANIN B; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROENDOCRINE TUMORS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84927593708     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3640     Document Type: Article

References (61)

1. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11(1):1-18.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13, 715 carcinoid tumors. Cancer. 2003;97(4):934-959.
3. Modlin IM, Oberg K, Chung DC, et al. A Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
4. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol. 2008;26(18):3063-3072.
5. Wiedenmann B, Ahnert-Hilger G, Kvols LK, Riecken EO. New molecular aspects for the diagnosis and treatment of neuroendocrine gastroenteropancreatic tumors. Ann N Y Acad Sci. 1994;733:515-525.
6. Zatelli MC, Torta M, Leon A, et al. Chromogranin A as a marker of neuroendocrine neoplasia: An Italian multicenter study. Endocr Relat Cancer. 2007;14(2):473-482.
7. Syversen U, Opsjøn SL, Stridsberg M, et al. Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies. J Clin Endocrinol Metab. 1996;81(12):4470-4475.
8. Stridsberg M, Husebye E. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur J Endocrinol. 1997;136(1):67-73.
9. Peracchi M, Gebbia C, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol. 2005;152(3):443-448.
10. Massironi S, Fraquelli M, Paggi S, et al. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis. 2009;41(1):31-35.
11. Ramachandran R, Bech P, Murphy KG, et al. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol (Oxf). 2012;76(6):831-836.
12. Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem. 2012;58(5):941-943.
13. Stridsberg M, Eriksson B, Fellström B, Kristiansson G, Tiensuu Janson E. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Peptides. 2007;139(1-3):80-83.
14. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuronspecific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96(12):3741-3749.
15. Rindi G, Klöppel G, Couvelard A, et al. TNMstaging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch. 2007;451(4):757-762.
16. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-712.
17. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes. 2009;16(1):72-78.
18. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: Implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853-860.
19. Stevenson R, Libutti SK, Saif MW. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors. JOP. 2013;14(2):155-157.
20. Giandomenico V, Modlin I, Ponten F, et al. Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science. Neuroendocrinology. 2013;98(1):16-30.
21. Bech P, Winstanley V, Murphy KG, et al. Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy. J Clin Endocrinol Metab. 2008;93(4):1246-1253.
22. Douglass J, McKinzie AA, Couceyro P. PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. J Neurosci. 1995;15(3):2471-2481.
23. Maletinska L, Maixnerova J, Matyskova R, et al. Cocaine- and amphetamine-regulated transcript (CART) peptide specific binding in pheochromocytoma cells PC12. Eur J Pharmacol. 2007;559(2-3):109-114.
24. Jensen PB, Kristensen P, Clausen JT, et al. The hypothalamic satiety peptide CART is expressed in anorectic and non-anorectic pancreatic islet tumors and in the normal islet of langerhans. FEBS Lett. 1999;447(2-3):139-143.
25. Wierup N, Sundler F. CART is a novel islet regulatory peptide. Peptides. 2006;27(8):2031-2036.
26. Landerholm K, Falkmer SE, Järhult J, Sundler F, Wierup N. Cocaineand amphetamine-regulated transcript in neuroendocrine tumors. Neuroendocrinology. 2011;94(3):228-36.
27. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer. 2006;42(8):1031-1039.
28. Stanley SA, Murphy KG, Bewick GA, et al. Regulation of rat pituitary cocaine- and amphetamine-regulated transcript (CART) by CRH and glucocorticoids. Am J Physiol Endocrinol Metab. 2004;287(3):E583-E590.
29. Wood WG, Wachter C, Scriba PC. Experiences using chloramine-T and 1, 3, 4, 6-tetrachloro-3 alpha, 6 alpha-diphenylglycoluril (iodogen) for radioiodination of materials for radioimmunoassay. J Clin Chem Clin Biochem. 1981;19(10):1051-1056.
30. Luo Y, Shen H, Liu HS, et al. CART peptide induces neuroregeneration in stroke rats. J Cereb Blood Flow Metab. 2013;33(2):300-310.
31. Fan J, Upadhye S, Worster A. Understanding receiver operating characteristic (ROC) curves. CJEM. 2006;8(1):19-20.
32. van der Zwan JM, Trama A, Otter R, et al. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49(11):2565-2578.
33. Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18(6):R253-R276.
34. Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: Utility of plasma methoxytyramine. J Clin Endocrinol Metab. 2005;90(4):2068-2075.
35. Eisenhofer G, Peitzsch M. Laboratory evaluation of pheochromocytoma and paraganglioma. Clin Chem. 2014;60(12):1486-1499.
36. Mannelli M, Lenders JW, Pacak K, Parenti G, Eisenhofer G. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab. 2012;26(4):507-515.
37. Zuber S, Wesley R, Prodanov T, Eisenhofer G, Pacak K, Kantorovich V. Clinical utility of chromogranin A in SDHx-related paragangliomas. Eur J Clin Invest. 2014;44(4):365-371.
38. Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, Linehan WM, Mannelli M, Friberg P, Grebe SK, Timmers HJ, Bornstein SR, Lenders JW. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer. 2011;18(1):97-111.
39. Aaltonen LA, Hamilton SR. Pathology and genetics of tumours of the digestive system. Hamilton SR, Aaltonen LA. Lyon, Oxford: IARC Press, Oxford University Press (distributor). 2000;314.
40. Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem. 2008;54(8):e1-e10.
41. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagdoi nostic odds ratio: A single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129-1135.
42. Bech PR, Martin NM, Ramachandran R, Bloom SR. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem. 2014;51(Pt 1):8-21.
43. Goetze JP, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as a biomarker in cardiovascular disease. Biomark Med. 2014;8(1):133-140.
44. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
45. Caplin ME, Pavel M, wikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233.
46. Guignat L, Bidart JM, Nocera M, Comoy E, Schlumberger M, Baudin E. Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer. 2001;84(6):808-812.
47. Bilek R, Safarik L, Ciprova V, Vlcek P, Lisa L. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res. 2008;57(Suppl 1):S171-S1719.
48. Unger N, Hinrichs J, Deutschbein T, et al. Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. Exp Clin Endocrinol Diabetes. 2012;120(8):494-500.
49. Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf). 2006;65(3):287-293.
50. Cotesta D, Caliumi C, Alo P, et al. High plasma levels of human chromogranin A and adrenomedullin in patients with pheochromocytoma. Tumori. 2005;91(1):53-58.
51. Srirangalingam U, Khoo B, Walker L, et al. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer. 2009;16(2):515-525.
52. Sekiya K, Ghatei MA, Salahuddin MJ, et al. Production of GAWK (chromogranin-B 420.493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. J Clin Invest. 1989;83(6):1834-1842.
53. Nolting S, Kuttner A, Lauseker M, et al. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: A single center experience and literature review. Cancers (Basel). 2012;4(1):141-155.
54. de Laat JM, Pieterman CR, Weijmans M, et al. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab. 2013;98(10):4143-4151.
55. Paik WH, Ryu JK, Song BJ, et al. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. J Korean Med Sci. 2013;28(5):750-754.
56. Duque M, Modlin IM, Gupta A, Saif MW. Biomarkers in neuroendocrine tumors. JOP. 2013;14(4):372-376.
57. Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 2013;8(5):e63364.
58. Calhoun K, Toth-Fejel S, Cheek J, Pommier R. Serum peptide profiles in patients with carcinoid tumors. Am J Surg. 2003;186(1):28-31.
59. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 2010;39(5):611-616.
60. Bloomston M, Al-Saif O, Klemanski D, et al. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: Lessons learned. J Gastrointest Surg. 2007;11(3):264-271.
61. Yamaguchi T, Fujimori T, Tomita S, et al. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol. 2013;8:65-1596-8-65.